Elizabeth Chiang

Ms. Elizabeth Chiang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
RMRohit Maini
Rohit Maini
DWDavid B. Wong
David B. Wong
DADaniel Addison
Daniel Addison
ECElizabeth Chiang
Elizabeth Chiang
SWSteven D. Weisbord
Steven D. Weisbord
HJHani Jneid
Hani Jneid

7 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HSHaleigh Dawn Stafford
Haleigh Dawn Stafford
JBJane Buell
Jane Buell
ECElizabeth Chiang
Elizabeth Chiang
URUma Ramesh
Uma Ramesh
MMMichael Migden
Michael Migden
DYDan Yaniv
Dan Yaniv
Skin cancer is the most common cancer diagnosis in the United States, with approximately one in five Americans expected to be diagnosed within their lifetime. Non-melanoma skin cancer is the most prevalent type of skin cancer, and as cases rise globally, physicians need reliable tools for early detection. Artificial intelligence has gained substantial interest as a decision support tool in medicine, particularly in image analysis, where deep learning has proven to be an effective tool. Because specialties such as dermatology rely primarily on visual diagnoses, deep learning could have many diagnostic applications, including the diagnosis of skin cancer. Furthermore, with the advancement of mobile smartphones and their increasingly powerful cameras, deep learning technology could also be utilized in remote skin cancer screening applications. Ultimately, the available data for the detection and diagnosis of skin cancer using deep learning technology are promising, revealing sensitivity and specificity that are not inferior to those of trained dermatologists. Work is still needed to increase the clinical use of AI-based tools, but based on the current data and the attitudes of patients and physicians, deep learning technology could be used effectively as a clinical decision-making tool in collaboration with physicians to improve diagnostic efficiency and accuracy.

25 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ECElizabeth Chiang
Elizabeth Chiang
HSHaleigh Dawn Stafford
Haleigh Dawn Stafford
JBJane Buell
Jane Buell
URUma Ramesh
Uma Ramesh
Moran AmitMoran Amit
Moran Amit
DYDan Yaniv
Dan Yaniv
It is widely known that tumor cells of basal and squamous cell carcinoma interact with the cellular and acellular components of the tumor microenvironment to promote tumor growth and progression. While this environment differs for basal and squamous cell carcinoma, the cellular players within both create an immunosuppressed environment by downregulating effector CD4+ and CD8+ T cells and promoting the release of pro-oncogenic Th2 cytokines. Understanding the crosstalk that occurs within the tumor microenvironment has led to the development of immunotherapeutic agents, including vismodegib and cemiplimab to treat BCC and SCC, respectively. However, further investigation of the TME will provide the opportunity to discover novel treatment options.

17 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
URUma Ramesh
Uma Ramesh
ECElizabeth Chiang
Elizabeth Chiang
HSHaleigh Dawn Stafford
Haleigh Dawn Stafford
JBJane Buell
Jane Buell
FMFrank Thomas Materia
Frank Thomas Materia
DYDan Yaniv
Dan Yaniv
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers worldwide, with an incidence that has increased over the past 30 years. Although usually curable with excision, cSCC can become widely metastatic and aggressive with poor outcomes. Whereas the clinical and radiographic extent of any cancer will always guide selection of treatment modality, pathological features of cSCC also play an important role in determining prognosis and, subsequently, the need for further therapy. Therefore, reviewing and summarizing the current literature regarding pathological prognostic indicators of cSCC is essential to improving clinical outcomes. The present literature review yielded depth of invasion, surgical margins, perineural invasion, extranodal extension, lymphovascular invasion, tumor grade, tumor subtype, premalignant lesions, and molecular markers as key prognostic indicators, all with varying recommendations for adjuvant therapy. Notably, some of these factors have not been incorporated into either the American Joint Committee on Cancer staging system (8th edition) or National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for cSCC. This review highlights a need for further research into these prognostic indicators and their role in determining the need for adjuvant treatment in head and neck cSCC.

10 October 2024 in Tumor Discovery
Verified
Journal Article
Open access
PDF file
ECElizabeth Chiang
Elizabeth Chiang
NZNeda Zarrin-Khameh
Neda Zarrin-Khameh
ARAlec B. Rezigh
Alec B. Rezigh
Sarcomatoid mesothelioma (SM) is a subtype of mesothelioma, a deadly cancer strongly related to asbestos exposure. Herein, we present the case of a 50-year-old female who presented with back pain and non-specific symptoms for approximately 9 months. The diagnostic investigation revealed a large, centrally necrotic mass in the thorax that appeared to arise from the mediastinum and surrounded vital structures, including the superior vena cava. A biopsy of the thoracic mass revealed SM. The patient developed hematemesis, and emergent endoscopy revealed a gastric ulcer composed of malignant SM cells, a rare finding in pleural mesothelioma. Her disease was too advanced for surgical resection and conventional therapy. She tragically died weeks after diagnosis. The findings of this report highlight the varied presentation of SM to underscore the importance of early diagnosis and treatment of patients in improving overall survival.

3 June 2026 in American Journal of Hematology
Verified
Journal Article
Open access
MLMing Y. Lim
Ming Y. Lim
RGRadhika Gangaraju
Radhika Gangaraju
OJOmid Jafari
Omid Jafari
ZYZihan Yang
Zihan Yang
JTJoyce W. T. Tiong
Joyce W. T. Tiong
ALAng Li
Ang Li
Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in 2 455 332 individuals with incident cancer encounters from 215 US health systems between 2018 and 2024. In the 12 months leading up to the cancer diagnosis, the period prevalence of CRB was 5.3% in the overall cohort, highlighting CRB as a common early presentation preceding cancer diagnosis. In the 12‐month window after cancer diagnosis, the cumulative incidence of CRB was 6.3% in the overall cohort, 7.0% in those receiving systemic antineoplastic therapy, and up to 15.0% among individuals on certain baseline anticoagulants. In addition to age, sex, and race, factors appreciably associated with CRB on multivariable analysis included cancer types, metastatic disease, systemic therapy, anticoagulant or antiplatelet use, higher comorbidity index, recent hospitalization, recent history of bleeding or VTE, and selective laboratory features (hemoglobin, platelets, albumin, eGFR). Furthermore, the onset of CRB as a time varying covariate was independently associated with mortality in multivariable adjusted analysis: intracranial hemorrhage (HR 4.17, 95% CI 4.11–4.24); gastrointestinal bleeding (HR 2.52, 95% CI 2.50–2.55); other bleeding (HR 2.46, 95% CI 2.44–2.49). Together, these findings reveal a substantial and overlooked risk of bleeding in cancer care and underscore a need for validated bleeding risk models that can be integrated alongside VTE prediction tools to guide personalized thromboprophylaxis decisions.